Mazyar Shadman, MD, MPH, presents a network meta-analysis evaluating Bruton tyrosine kinase (BTK) inhibitors in high-risk relapsed/refractory CLL, showing that zanubrutinib demonstrated the greatest efficacy in reducing progression and death compared with other BTK inhibitors and treatments.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.